Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18 F-FDG and 18 F-DCFPyL PET/CT. 18 F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18 F-FDG, 18 F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.
. A 58-year-old man with known clear cell RCC metastases to the skeleton was imaged contemporaneously with two PET/CT examinations, one with 18 F-FDG and a second with 18 F-DCFPyL, a small molecule inhibitor of PSMA. The maximum intensity projection images from the two examinations ( 18 F-FDG, A, and 18 F-DCFPyL, B) demonstrate concordance of multiple radiotracer-avid lesions including the proximal right humerus and both iliac bones (red arrowheads). However, additional subtle sites of 18 F-DCFPyL uptake are noted that do not have corresponding 18 F-FDG uptake (blue arrows). These sites include subtle endosteal scalloping of the left posterior ninth rib and the left iliac bone without accompanying 18 F-FDG uptake (C and E, blue arrows). In contrast, the axial 18 F-DCFPyL PET/CT images demonstrated moderate radiotracer uptake at these sites (D, SUV max (lean body mass corrected) 3.2, blue arrow and F, 18 F-DCFPyL SUV max 2.7, blue arrow).
FIGURE 2.
Large lytic lesions were present in the posterior aspects of both iliac bones in this patient, and both sites were found to have intense uptake of both radiotracers ( 18 F-FDG in A and B and 18 F-DCFPyL in C and D, red arrowheads). However, 18 F-DCFPyL uptake was both visually and quantitatively higher than 18 F-FDG. For the right iliac lesion, 18 F-FDG uptake yielded SUV max of 3.3, while for the same lesion 18 F-DCFPyL uptake generated SUV max of 16.6. For the left iliac, 18 F-FDG SUV max was 4.0 while 18 F-DCFPyL SUV max was 13.9. In aggregate, our findings in this patient with metastatic clear cell RCC are suggestive that 18 F-DCFPyL may able to identify more lesions and has higher tumor uptake than 18 F-FDG. Although a significant body of work has examined the role of 18 F-DCFPyL and other small molecule inhibitors targeted against PSMA in the detection of prostate cancer, 1-4 the use of such radiotracers for non-prostate applications has been limited to date. 5, 6 This is despite the fact that PSMA is highly expressed on the tumor neovasculature of many solid tumors, including RCC. 7, 8 Indeed, a previous case report has demonstrated the ability of a 68 Ga-labeled small molecule inhibitor of PSMA ( 68 Ga-PSMA) to identify sites of disease in a patient with metastatic clear cell RCC. 5 In that report, the authors noted concordance between 18 F-FDG and 68 Ga-PSMA uptake for all described lesions, though the 68 Ga-PSMA PET acquisition was notable for improved lesion conspicuity. In combination with the earlier findings utilizing 68 Ga-PSMA, this report confirms that further study with PSMA radiotracers in metastatic RCC is warranted.
